Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.97 EUR | +1.46% | +13.72% | +21.86% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 7.151 | 11.24 | 24.01 | 29.63 | 64.46 | 133.6 |
Enterprise Value (EV) 1 | 45.84 | 50.17 | 61.48 | 65.32 | 83.39 | 157.7 |
P/E ratio | 5.73 x | 2.11 x | 11.1 x | 17.2 x | 9.91 x | 71.4 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.21 x | 0.33 x | 0.64 x | 0.75 x | 1.4 x | 2.62 x |
EV / Revenue | 1.35 x | 1.49 x | 1.63 x | 1.64 x | 1.81 x | 3.1 x |
EV / EBITDA | 7.64 x | 10.4 x | 9.72 x | 11.3 x | 16.9 x | 19.7 x |
EV / FCF | -17 x | -191 x | 108 x | 24.9 x | -2.69 x | -33.3 x |
FCF Yield | -5.89% | -0.52% | 0.93% | 4.01% | -37.2% | -3% |
Price to Book | -0.37 x | -0.78 x | -1.95 x | -2.97 x | 1.6 x | 3.13 x |
Nbr of stocks (in thousands) | 17,027 | 17,027 | 17,027 | 17,027 | 1,67,868 | 1,67,868 |
Reference price 2 | 0.4200 | 0.6600 | 1.410 | 1.740 | 0.3840 | 0.7960 |
Announcement Date | 25/04/19 | 08/05/20 | 26/04/21 | 21/03/22 | 27/03/23 | 21/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 34.06 | 33.59 | 37.64 | 39.72 | 46.01 | 50.93 |
EBITDA 1 | 6.002 | 4.816 | 6.326 | 5.761 | 4.932 | 8.022 |
EBIT 1 | 5.017 | 3.833 | 5.235 | 4.51 | 4.042 | 4.388 |
Operating Margin | 14.73% | 11.41% | 13.91% | 11.35% | 8.79% | 8.62% |
Earnings before Tax (EBT) 1 | 2.861 | 2.116 | 3.38 | 2.747 | 2.14 | 3.247 |
Net income 1 | 1.249 | 5.327 | 2.165 | 1.723 | 0.834 | 1.871 |
Net margin | 3.67% | 15.86% | 5.75% | 4.34% | 1.81% | 3.67% |
EPS 2 | 0.0734 | 0.3129 | 0.1272 | 0.1012 | 0.0387 | 0.0111 |
Free Cash Flow 1 | -2.702 | -0.2628 | 0.5719 | 2.618 | -31.01 | -4.736 |
FCF margin | -7.93% | -0.78% | 1.52% | 6.59% | -67.4% | -9.3% |
FCF Conversion (EBITDA) | - | - | 9.04% | 45.45% | - | - |
FCF Conversion (Net income) | - | - | 26.41% | 151.97% | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 25/04/19 | 08/05/20 | 26/04/21 | 21/03/22 | 27/03/23 | 21/03/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 38.7 | 38.9 | 37.5 | 35.7 | 18.9 | 24 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 6.446 x | 8.085 x | 5.923 x | 6.195 x | 3.838 x | 2.997 x |
Free Cash Flow 1 | -2.7 | -0.26 | 0.57 | 2.62 | -31 | -4.74 |
ROE (net income / shareholders' equity) | -6.34% | -31.5% | -16.3% | -16% | 5.46% | 4.8% |
ROA (Net income/ Total Assets) | 7.23% | 5.25% | 6.54% | 5.46% | 3.03% | 2.4% |
Assets 1 | 17.27 | 101.5 | 33.1 | 31.55 | 27.55 | 78.1 |
Book Value Per Share 2 | -1.150 | -0.8500 | -0.7200 | -0.5900 | 0.2400 | 0.2500 |
Cash Flow per Share 2 | 0.1100 | 0.1000 | 0.1100 | 0.1000 | 0.1100 | 0.0500 |
Capex 1 | 1.03 | 2.42 | 1.48 | 1.92 | 35.6 | 4.12 |
Capex / Sales | 3.03% | 7.19% | 3.92% | 4.83% | 77.42% | 8.08% |
Announcement Date | 25/04/19 | 08/05/20 | 26/04/21 | 21/03/22 | 27/03/23 | 21/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+21.86% | 174M | |
+21.98% | 43.92B | |
+24.56% | 23.09B | |
+19.25% | 15.35B | |
+14.03% | 13.61B | |
+46.40% | 12.02B | |
-10.14% | 7B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.07% | 5.6B |
- Stock Market
- Equities
- LAVI Stock
- Financials Lavipharm S.A.